Efficacy and safety of selexipag in real-life in patients with pulmonary arterial hypertension: early results of RAMPHA study
Event: ESC Congress 2022
Topic: Pulmonary Hypertension
Session: Focus on the pulmonary vascular bed
Efficacy and safety of selexipag in patients with pulmonary arterial hypertension in real-life: early results of RAMPHA study
Event: Heart Failure 2022
Topic: Pulmonary Hypertension
Session: Focus on the right side
Security of neurohormonal blocking with sacubitril / valsartan, iSGLT2 and mineralocorticoid receptor antagonist in patients with heart failure with reduced eyection fraction and diabetes mellitus
Event: Heart Failure 2019
Topic: Cardiovascular Pharmacotherapy
Session: Pharmacology and Pharmacotherapy
Sacubitril valsartan in real life: tolerance, clinical evolution and remodeled long term
Event: Heart Failure 2019
Topic: Cardiovascular Pharmacotherapy
Session: Pharmacology and Pharmacotherapy
Experience using sacubitril/valsartan in real life: tolerability and clinical evolution in a long term
Event: Heart Failure 2018
Topic: Systolic Ventricular Dysfunction
Session: Chronic Heart Failure – Pathophysiology and Mechanisms
ESC 365 is supported by
